Clinical Trial Update: A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients [Phase 2]

View source ↗

Summary

Phase 2 trial investigating whether lowering parathyroid hormone with etelcalcetide (Parsabiv) affects serum calcification propensity in dialysis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Parsabiv (etelcalcetide)

Snippet

Sponsor: Prim. Priv. Doz. Dr. Daniel Cejka | Conditions: End Stage Renal Disease | Phase 2 | Status: COMPLETED